The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments |
| |
| Affiliation: | 1. Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Australia;2. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia;3. Alfred Health Radiation Oncology Services, Australia;4. School of Clinical Medicine, University of Cambridge, UK;5. Department of Epidemiology and Preventive Medicine, Monash University, Australia;6. Cancer Epidemiology Division, Cancer Council Victoria, Australia;7. Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Australia;8. Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Australia;9. Central Clinical School, Monash University, Australia;1. Northern Sydney Cancer Centre, Radiation Oncology Unit, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia;2. Northern Clinical School, University of Sydney, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia;3. Genesis Care, Mater Hospital, North Sydney, Sydney, NSW, Australia;4. Department of Nuclear Medicine and PET, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia;5. National Health and Medical Research Council, Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia;1. University of Utah, Huntsman Cancer Institute, Department of Radiation Oncology, Salt Lake City, UT;2. University of Utah School of Medicine, Department of Radiation Oncology, Salt Lake City, UT;3. University of Utah, Department of Radiology and Imaging Services, Salt Lake City, UT;2. Department of Radiation Oncology, University Hospitals, Case Western Reserve, Cleveland, Ohio |
| |
| Abstract: | High risk prostate cancer (HR-PrCa) is a subset of localized PrCa with significant potential for morbidity and mortality associated with disease recurrence and metastasis. Radiotherapy combined with Androgen Deprivation Therapy has been the standard of care for many years in HR-PrCa. In recent years, dose escalation, hypo-fractionation and high precision delivery with immobilization and image-guidance have substantially changed the face of modern PrCa radiotherapy, improving treatment convenience and outcomes. Ultra-hypo-fractionated radiotherapy delivered with high precision in the form of stereotactic body radiation therapy (SBRT) combines delivery of high biologically equivalent dose radiotherapy with the convenience of a shorter treatment schedule, as well as the promise of similar efficacy and reduced toxicity compared to conventional radiotherapy. However, rigorous investigation of SBRT in HR-PrCa remains limited. Here, we review the changes in HR-PrCa radiotherapy through dose escalation, hypo- and ultra-hypo-fractionated radiotherapy boost treatments, and the radiobiological basis of these treatments. We focus on completed and on-going trials in this disease utilizing SBRT as a sole radiation modality or as boost therapy following pelvic radiation. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
